Introduction Vitamin D 3 supplementation has been reported to prevent lung infections and increase the gene expression of antimicrobial peptides such as cathelicidin. We investigated the effect of vitamin D 3 supplementation on the antimicrobial activity of airway surface liquid (ASL) in human subjects. Since smoking can increase the risk of respiratory infections, we also investigated the effect of smoking in the cathelicidin response to vitamin D 3 in human airway epithelia in vitro. Methods This study is a subanalysis of single-centre community-based randomised placebo-controlled double-blind trial. Participants were randomised to receive 1000 international units per day of oral vitamin D 3 or identical placebo for 90 days. Blood and ASL samples were collected preintervention and postintervention. 105 participants were originally enrolled, 86 completed the trial, and due to low protein concentration in the samples, 40 participants were finally analysed. Our primary outcome was ASL antimicrobial activity. We also considered secondary outcomes including changes in serum concentration of 25-hydroxyvitamin D 3 (25(OH)D 3 ), 1,25-hydroxyvitamin D 3 , calcium and parathyroid hormone (PTH). In addition, we studied the effect of cigarette smoke extract (CSE) exposure to primary human airway epithelial cell cultures on the gene expression of cathelicidin in response to vitamin D 3 and expression of CYP27B1 (1-alpha hydroxylase), responsible for vitamin D 3 activation. Results Vitamin D 3 supplementation significantly increased both ASL antimicrobial activity and serum concentration of 25(OH)D 3 . In a subgroup analysis, we found that smokers did not increase their baseline antimicrobial activity in response to vitamin D 3 . Exposure to CSE on human airway epithelia decreased baseline CYP27B1 gene expression and cathelicidin response to 25(OH)D 3 . Conclusion Vitamin D 3 supplementation for 90 days increases ASL antimicrobial activity. Data from this preliminary study suggest that smoking may alter the ability of airway epithelia to activate vitamin D 3 and increase the gene expression of cathelicidin antimicrobial peptide.
Trial registration number NCT01967628; Post-results.
IntroductIon
Vitamin D 3 is a liposoluble vitamin naturally present in very few dietary sources and generated by the skin when exposed to sunlight. Despite supplementing food with vitamin D, a great proportion of the world's population is still deficient. [1] [2] [3] Vitamin D deficiency is found more often in smokers with accelerated lung function decline and in patients with severe chronic obstructive pulmonary disease (COPD). [4] [5] [6] [7] [8] One of the proposed mechanisms for lung function decline and development of chronic respiratory diseases is the occurrence of airway infections. 9 10 Since low vitamin D 3 levels increase susceptibility to respiratory infections in both smokers and non-smokers, [11] [12] [13] [14] it is critical to investigate the effect of vitamin D supplementation on airway antimicrobial activity in both populations.
Vitamin D 3 in the bloodstream is hydroxylated by the liver into 25-hydroxyvitamin D 3 (25(OH)D 3 ). This form is used conventionally to measure vitamin D 3 sufficiency. Thereafter, the 1α-hydroxylase, constitutively Open Access active in the kidney, activated macrophages and in airway epithelia converts 25(OH)D 3 into 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ). 15 The active form of vitamin D 3 binds to the intracellular vitamin D receptor to activate vitamin D response elements to modulate the gene expression of multiple pathways involved in serum calcium metabolism and bone remodelling. 16 It also upregulates the expression of antimicrobial peptides (AMPs) present in the airway surface liquid (ASL), such as human cathelicidin (LL-37) and human beta defensins (hBDs) secreted by airway epithelia and immune cells. 15 17-19 AMPs can kill pathogens within minutes as a first line of defence and their impairment is associated with the development of airway disease. 20 Various mechanisms can impair AMP activity, such as: decreased production, decreased pH, increased ionic strength, increased host and pathogen proteases and increased polymerisation of AMPs with DNA/filamentous-actin. [21] [22] [23] [24] [25] [26] We hypothesised that vitamin D 3 supplementation would increase human ASL antimicrobial activity in vivo.
To test this hypothesis, we investigated the antimicrobial activity of biobanked ASL samples collected through bronchoscopy of a cohort of smoking and non-smoking participants that randomly received either 1000 international units (IU) of vitamin D 3 /day or matching placebo for 90 days. 27 We also investigated the effect of smoking in the airway response to vitamin D 3 in vivo and in vitro.
Methods

study design
This study design has been previously published. 27 Briefly, this is a single-centre, community-based, randomised, placebo-controlled double-blind trial. This pilot study investigated the effects of vitamin D 3 supplementation on the innate immunity of the lung. The University of Iowa Hospital and Clinics Institutional Review Board approved the trial (IRB# 200607708). Written consent was obtained from all the subjects. This trial is registered on ClinicalTrials. gov (NCT01967628).
Participants
We recruited subjects 18-60 years old from the Iowa City community. We excluded participants if they were taking vitamin supplements within the previous 3 months, had any history of positive tuberculin test, pneumonia within 3 years, airway infection or antibiotic use within 6 weeks or vaccination within 1 month of enrolment. Additional exclusion criteria included any prescription medication except: oral contraceptives, topical medications, selected antidepressants, levothyroxine, acid reflux treatment, over-the-counter antihistamine or sleep aids. Participants were also excluded if they had one of these conditions: pregnancy, breastfeeding, asthma, diabetes, heart disease or allergy to lidocaine. We also excluded subjects that did not complete their second visit or if ASL collection was not possible due to technical limitations during bronchoscopy (figure 1).
Interventions and randomisation
After informed consent was signed and pregnancy was excluded, the subject's blood was drawn to assess 25(OH) D 3 , 1,25(OH) 2 D 3 , parathyroid hormone (PTH) and calcium serum concentration. Thereafter, a bronchoscopy was performed at the University of Iowa Hospitals and Clinics (Iowa City, Iowa, USA) as previously described. 27 To collect the ASL, three sponges were placed, one at a time, on the right main stem bronchus or bronchus intermedius for 30 s and then eluted with 1 mL of isotonic saline into a 1.5 mL tube. The tube was vortexed for 1 min and the sponges removed. The samples were stored at −80°C. After collections, participants were randomised using a computer-generated list to receive either vitamin D 3 (1000 IU/day, 90 000 IU total) or matching placebo. Study participants, the clinical research team and the sponsoring agency were blinded to intervention assignments.
outcomes
The primary outcome analysed for this subanalysis was ASL antimicrobial activity preintervention and postintervention (vitamin D 3 or placebo). We considered secondary outcome changes in serum concentration of 25 Open Access the difference between the smoking and non-smoking groups in response to vitamin D 3 .
AsL protein concentration
Briefly, aliquots were thawed at 4°C and total protein concentration was measured by a Bradford assay, interpolating samples to a bovine serum albumin standard curve. We adjusted sample concentrations with normal saline to 100 µg/mL of total protein. This threshold was selected prior the antimicrobial activity assay based on preliminary antimicrobial activity studies to minimise sample dilution and yet still be able to include the majority of the subjects.
AsL antimicrobial activity
We added 10 µL of protein-corrected ASL (100 µg/ mL) or protein uncorrected into a 96-well plate. Then, samples were challenged with 10 µL of a solution containing bioluminescent Staphylococcus aureus Xen 29 (~5×10 6 colony forming units) injected by the precision peristaltic pump in the luminometer. After 4 min, we measured relative light units (RLU) as a surrogate for live bacteria as previously described. 21 To minimise observer bias, we randomised the samples onto the plate. The luminometer injected the bacteria and measured RLU automatically, and the conditions were not revealed until the experiment was completed.
Macrophage microarray
RNA preparation, quality analysis and microarray analysis were done as previously described. 28 Measurements of genome-wide macrophage messenger RNA expression and analysis were done as previously described 27 (Gene Expression Omnibus (GEO) accession # GSE56583).
human airway epithelia exposure to cigarette smoke extract Differentiated primary human airway epithelia were cultured at the air liquid interface as previously described. 29 We switched cultures to minimum essential media, with and without 25(OH)D 3 (10 -7 M) or 1,25(OH) 2 D 3 (10 −7 M) in the presence or absence of 3% cigarette smoke extract (CSE). 7 15 We changed the media every day for the duration of the experiment and analysed by quantitative (q)PCR the relative gene expression of CYP27B1 which codes for 1α-hydroxylase and cathelicidin antimicrobial peptide (CAMP) which codes for the cationic antimicrobial peptide LL-37. First, we exposed cells to 25(OH)D 3 or 1,25(OH) 2 D 3 or CSE alone for 4 days and quantified the relative gene expression of CAMP and CYP27B1 (n=4). In separate experiments, we analysed the response to 25(OH)D 3 (n=8) or 1,25(OH) 2 D 3 (n=5) in epithelia exposed overnight to CSE or control and analysed the relative gene expression of CAMP by qPCR. compliance In the vitamin D 3 group, 46% of subjects were compliant and 39% had residual doses. The mean number of missed capsules was approximately 6.5 capsules (range 1-15) for an average of total missed vitamin D 3 of 6500 IU per subject. Four treated subjects did not bring back their pill bottles for compliance analysis. In the placebo group, 43% of subjects completed full therapy and 53% had missed doses. The mean number of missed capsules was 8.8 (range 1-30). One placebo subject did not bring back the pill bottle for analysis.
statistical analysis
Data are expressed as mean ± SEM For ASL antimicrobial activity, we used raw RLU and for the LL-37 experiments we normalised data as per cent of control using this formula:
Per cent of live bacteria = RLU from sample RLU from controlvehicle × 100
To determine the statistical significance between preintervention and postintervention (vitamin D 3 and placebo), we used paired t-tests. We used multiple comparison analysis of variance (ANOVA) and Kruskal-Wallis to compare three or more conditions in the antibody treated ASL and LL-37. We also used Pearson test to calculate correlation coefficients. We did not exclude improbable data. Data analysis was performed using GraphPad Prism V.6.00 (GraphPad Software, California, USA). Power analysis were performed using G*Power V.3.1.9.2 (Germany).
resuLts
Participant demographics
We first analysed the differences in demographics between subjects receiving vitamin D 3 or placebo (table 1) . The vitamin D 3 group had slightly more percentage of white, male and non-smoking participants compared figure 3 ).
Vitamin d 3 increases AsL antimicrobial activity
We investigated the effect of vitamin D 3 supplementation on ASL antimicrobial activity using a bioluminescent bacterial challenge. We challenged ASL samples with bioluminescent bacteria and measured live bacteria by RLU after 2 min as a surrogate of antimicrobial activity. We interpreted a reduction in live bacteria after challenge in RLU as increased antimicrobial activity. We found that subjects taking vitamin D 3 supplementation for 90 days had significantly lower live bacteria in RLU after challenge compared with their baseline (95% CI of the difference −1122 to −40.37; p=0.0365 by paired t-test) (figure 4A). Placebo treatment did not significantly decrease the number of live bacteria after challenge compared with baseline (95% CI of the difference −1170 to 198.5; p=0.1532 by paired t-test) (figure 4B). These results suggest that vitamin D 3 supplementation for 90 days increases baseline ASL antimicrobial activity.
25(oh)d 3 deficiency was associated with lower AsL antimicrobial activity
We hypothesised that subjects with serum vitamin D 3 deficiency (<20 ng/mL) would have lower ASL antimicrobial activity compared with non-deficient subjects (≥20 ng/ mL). To investigate the effect of vitamin D 3 deficiency on ASL antimicrobial activity, we paired RLU values in the samples with their respective serum 25(OH)D 3 regardless of allocation group (vitamin D 3 or placebo) or whether they were baseline or postintervention samples. Thereafter, we compared the amount of live bacteria after Open Access Open Access challenge in the ASL samples with a clinically deficient 25(OH)D 3 serum concentration to the samples with non-deficient levels. We found that ASL samples associated with vitamin D 3 deficiency had significantly more live bacteria after challenge compared with non-deficient subjects (6394±289, n=16 vs 5646±129, n=64 respectively, p=0.0136 by unpaired t-test). These data suggest that vitamin D 3 deficiency is associated with a decrease in ASL antimicrobial activity.
LL-37 antibody inhibits AsL antimicrobial activity
We hypothesised that ASL antimicrobial activity is dependent on LL-37 activity. Since we were limited by volume and concentration of the samples, we took an indirect approach to investigate this hypothesis. We used an LL-37 antibody to neutralise the effect of cathelicidin, one of the antimicrobial peptides regulated by the vitamin D response elements, as previously described.
23 30 31 When we coincubated increasing concentrations of LL-37 antibody with synthetic LL-37, we observed inhibition of the antimicrobial activity in a concentration-dependent manner compared with control antibody (goat IgG, antimouse IgG) (figure 5A). We also tested the effect of increasing doses of LL-37 antibody on seven random preintervention ASL samples from non-smokers, resulting in decreased ASL antimicrobial activity in a concentration-dependent manner (figure 5B). When we treated ASL samples with control antibody at maximal concentration, we observed no effect compared with ASL without the antibody at 4 min after bacterial challenge ( figure 5C ). These results suggest that LL-37 antibody can inhibit ASL antimicrobial activity.
Anti-LL-37 blocks the vitamin d 3 -induced improvement of AsL antimicrobial activity
We hypothesised that LL-37 antibody would block the increased antimicrobial activity of the ASL samples from non-smokers postvitamin D 3 supplementation. When we coincubated ASL samples previtamin D 3 and postvitamin D 3 with LL-37 antibody (70 nM), the increased antimicrobial activity was significantly reversed (figure 5D).
Vitamin d 3 does not increase cathelicidin gene expression in alveolar macrophages
AMPs in ASL can come from two main sources: inflammatory cells such as macrophages and airway epithelial cells. Since it has been reported that vitamin D 3 increases LL-37 in both human macrophages and airway epithelia, 15 32 we investigated the change in CAMP gene expression in human alveolar macrophages from smokers and non-smokers treated with vitamin D 3 . We found no significant difference in either smokers or non-smokers (fold change −1.05, p=0.33 in non-smokers and fold change −1.15, p=0.16 in smokers). These results suggest that airway epithelia might be responsible for the increase in ASL antimicrobial activity due to vitamin D 3 . Open Access hydroxylase, the enzyme that converts vitamin D 3 into its active form ( figure 7A,B) . 15 This decrease in CYP27B1 is consistent with a self-regulatory loop that decreases excessive vitamin D 3 activation. 15 33 smokers did not increase AsL antimicrobial activity In a post hoc analysis, we investigated the effect of smoking in the antimicrobial activity of the ASL. When we analysed the ASL from smokers and the non-smokers, only the non-smokers significantly decreased the number of live bacteria compared with their baseline (baseline vs vitamin D 3 in non-smokers) (figure 6A). Although the smokers had a small sample size, we did not observe any difference ( figure 6B ). Using the data from the non-smokers that received vitamin D 3 we determined an effect size of 0.8462, and using a power of 0.8 and alpha of 0.05, we calculated an a priori sample size of at least 14 subjects to detect a difference in the smokers.
cse decreased cAMP gene expression response to vitamin d 3 Since smokers did not improve their baseline antimicrobial activity when supplemented with vitamin D 3 , we investigated the effect of CSE exposure on CAMP gene expression in response to 25(OH)D 3 in vitro. We found that airway epithelial cells exposed to CSE and supplemented with 25(OH)D 3 had a smaller increase in CAMP gene expression compared with unexposed cells ( figure 7C ). We then investigated if supplementing Open Access 1,25(OH) 2 D 3 would overcome this decreased response in CAMP gene expression in CSE-exposed human airway epithelial cells. We found a similar increase in CAMP gene expression in both CSE-exposed and unexposed human airway epithelial cells in response to 1,25(OH) 2 D 3 ( figure 7D) 34 while others do not show such protection. 35 To our knowledge, this is the first in vivo study demonstrating that vitamin D 3 supplementation increases baseline human ASL antimicrobial activity using a standardised sample and inoculum.
In In addition, we found that ASL samples matched with a deficient vitamin D 3 serum concentration had significantly lower antimicrobial activity compared with samples paired with sufficient vitamin D 3 . These results are consistent with epidemiological studies that report that low vitamin D 3 levels increase the susceptibility to respiratory infections. [11] [12] [13] [14] We speculate that vitamin D 3 increases the ASL antimicrobial activity by upregulating gene expression of antimicrobial peptides like cathelicidins. 15 17-19 Since we did not find any difference in CAMP gene expression in macrophages, we hypothesised that the airway epithelium was responsible for the increase in ASL antimicrobial activity due to vitamin D 3 . Since we were limited by the volume and concentration of the samples, we took an indirect approach to confirm our hypothesis. As a proof of concept, we used an LL-37 antibody to neutralise the effect of LL-37 in the ASL. 23 30 We found that the improvement in ASL antimicrobial activity after vitamin D 3 supplementation was reversed when the ASL was treated with an LL-37 antibody. This effect can be in part due to both functional inhibition of this antimicrobial peptide and/or decreased synergism between LL-37 and other antimicrobial peptides such as hBDs. 22 Future studies should consider sampling more volume of ASL to be able to measure directly AMPs. Nonetheless, He et al found that Vitamin D 3 supplementation for 14 weeks increased the concentration of cathelicidin in both plasma and saliva in healthy subjects. 36 We also did a subgroup analysis on the subjects who were smokers, and found compelling results that suggest that they did not increase their ASL antimicrobial activity after vitamin D 3 supplementation. We acknowledge that our sample size was small and we might be underpowered to detect the difference. However, our in vitro study showing that human airway epithelial cells exposed to CSE in vitro had decreased cathelicidin gene expression in response to 25(OH)D 3 strongly supports the feasibility of our in vivo finding, despite lack of power. In addition, it has been reported that cigarette smoke exposure is negatively correlated with LL-37 in human saliva. 37 Furthermore, patients with COPD who have high risk of frequent exacerbations also have decreased plasma levels of LL-37 compared with control subjects. 38 These results warrant further evaluation in larger sample sizes.
Our in vitro results also suggest that one of the mechanisms responsible for this finding is that cigarette smoke reduces gene expression coding for the enzyme responsible for converting vitamin D 3 into its active form. This is consistent with a prior report that exposure to cigarette smoke was associated with impaired ability of human airway epithelia to hydroxylate 25(OH)D 3 to 1,25(OH) 2 D 3 .
7 When we used the active form of vitamin D 3 , we found a similar increase in cathelicidin gene expression regardless of CSE exposure. Heulens et al also reported that human macrophages exposed to CSE had a similar increase in cathelicidin gene expression in response to 1,25(OH) 2 D 3 compared with unexposed cells. 39 Given that cigarette smoke exposure (1) decreased cathelicidin gene expression in response to 25(OH)D 3 , (2) decreased CYP27B1 gene expression and (3) did not affect the cathelicidin gene expression response to active vitamin D 3 , we propose that one mechanism by which CSE impairs airway innate immunity is by decreasing local vitamin D 3 activation.
Another plausible explanation for decreased response to vitamin D 3 in the smokers is different processing of hCAP18, the parent molecule of LL-37 before being processed or LL-37 itself. Smoking increases the concentration of proteolytic proteins such as cathepsin D and neutrophils elastase. 40 41 Proteolysis by these enzymes
Open Access can decrease LL-37 in the airways and its antimicrobial activity. 23 Furthermore, although cathelicidin is a relevant antimicrobial peptide, other antimicrobials that have a vitamin D response element like hBDs might be also increased by vitamin D 3 supplementation. 42 Herr et al reported that airway epithelium exposed to smoke significantly reduced hBD-2 and antimicrobial activity in vitro. In addition, former or current smokers with pneumonia had decreased concentration of hBD-2 in pharyngeal washing fluid compared with non-smokers. 43 Our study has several strengths, including analysing ASL samples from the same subjects before and after randomised intervention. We also recognise that we have several limitations such as the small number of samples in the subgroup analysis and the indirect approach to assess the role of LL-37 in the ASL antimicrobial activity using a neutralising antibody. Finally, it is conceivable that smokers require even higher doses of vitamin D 3 and/or a longer duration of treatment.
conclusions
We provide evidence that vitamin D 3 supplementation for 90 days increases ASL antimicrobial activity in non-smoking humans. We presume that this effect occurs via an increase in ASL AMPs. Conversely, smoking participants did not improve their ASL antimicrobial activity, and we propose that the mechanism is, in part, due to impaired conversion of vitamin D 3 to its active form leading to a decreased expression of airway AMPs. Future studies with a higher number of subjects are required to confirm the effect modification of smoking in the ASL antimicrobial activity in response to vitamin D 3 in vivo, as well as the effect of active vitamin D 3 in the airway antimicrobial activity of smokers.
